Health Care and Biotech

Resonance Health has captured the imagination of NDF Research with its world-leading MRI diagnostics, resulting in an initiation of coverage.

Fisher & Paykel Healthcare has signalled robust growth in its hospital applications but remains hindered by a patent dispute with ResMed.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Ahead of the release of important data on CSL’s heart disease product, brokers acknowledge potentially substantial upside.

Michael Gable of Fairmont Equities suggests there may yet be further downside to come for Healthscope.

Healthscope has rattled the market, announcing a very weak September quarter and flagging the prospect of a flat revenue outcome in FY17 if the trend continues.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Moelis upgrades medical imaging software company Pro Medicus to Buy, citing an extensive growth opportunity in the US.

AdAlta, a Melbourne-based drug developer, recently listed on ASX and NDF Research takes up coverage of the stock.

Sigma Pharmaceuticals is expanding its reach into hospital pharmacy while maintaining a stable base business. Brokers welcome the increased diversity.

Cochlear has taken advantage of sales growth to reinvest in development. While brokers approve, they question whether the stock’s current premium is justified.

Recently listed ResApp Health has developed a digital system that could revolutionise the diagnosis of respiratory disorders.